The commercial operations sector focuses on introducing and selling medical products and technologies for LuJian. It's a key platform for domestic substitution and independent medical device development. Our "Automatic Troclose and Suture Device," imported in 2022, is a Class III innovative device that secured FDA and CE certification in 2016. With $10 million in funding, it's marketed in Europe and the US, and recognized by the FDA as a "Laparoscopic Surgery Access Innovator."

The sector is actively managing landing projects, initiating market activities, and collaborating with multiple domestic hospitals for multi - center clinical validation. By leveraging research resources, we aim to widely promote these innovative clinical achievements. We're also opening up nationwide agency opportunities with provincial medical device firms to boost product application and enhance laparoscopic surgery outcomes.